{"protocolSection":{"identificationModule":{"nctId":"NCT04664933","orgStudyIdInfo":{"id":"K (2020) 32"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)","officialTitle":"Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study"},"statusModule":{"statusVerifiedDate":"2023-05","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-12-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-11-30","studyFirstSubmitQcDate":"2020-12-06","studyFirstPostDateStruct":{"date":"2020-12-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-05-23","lastUpdatePostDateStruct":{"date":"2023-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Director","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"Hui-Sheng Chen","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation."},"conditionsModule":{"conditions":["Stroke, Ischemic","Intravascular Thrombosis","Mechanical Thrombectomy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intra-arterial administration of 3-n-butylphthalide","type":"EXPERIMENTAL","description":"Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.","interventionNames":["Drug: Intra-arterial administration of neuroprotective agents"]}],"interventions":[{"type":"DRUG","name":"Intra-arterial administration of neuroprotective agents","description":"Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min","armGroupLabels":["Intra-arterial administration of 3-n-butylphthalide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of server adverse events","description":"server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.","timeFrame":"48 hours"}],"secondaryOutcomes":[{"measure":"Proportion of patients with modified Rankin Score 0 to 1","description":"Proportion of patients with modified Rankin Score 0 to 1","timeFrame":"90 days"},{"measure":"Proportion of patients with modified Rankin Score 0 to 2","description":"Proportion of patients with modified Rankin Score 0 to 2","timeFrame":"90 days"},{"measure":"Modified Rankin Score","description":"Modified Rankin Score","timeFrame":"90 days"},{"measure":"Decrease in national institutes of health stroke scale (NIHSS)","description":"Decrease in NIHSS scoring at 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Proportion of symptomatic intracranial hemorrhage (sICH)","description":"sICH was defined as 4 or more increase in NIHSS caused by hemorrhage","timeFrame":"48 hours"},{"measure":"Proportion of intraparenchymal hemorrhage (PH1 and PH2)","description":"Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Changes in cerebral edema","description":"Cerebral edema was determined by cerebral volume or midline shift","timeFrame":"48 hours"}],"otherOutcomes":[{"measure":"Differences in serum factors levels and blood gas in diverse vessel region","description":"Differences in serum factors levels and blood gas in diverse vessel region","timeFrame":"Hour 0"},{"measure":"Changes in serum factors levels","description":"changes in serum factors levels before and at different timepoints after recanalization","timeFrame":"30 minutes, 24 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age â‰¥18 years;\n2. Acute ischemic stroke patients who is eligible for endovascular treatment;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\\<80000/mm3);\n3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n5. Unsuitable for this clinical studies assessed by researcher.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Department of Neurology, General Hospital of Northern Theater Command","status":"RECRUITING","city":"Shenyang","zip":"110016","country":"China","contacts":[{"name":"Hui-Sheng Chen, Ph.D.","role":"CONTACT","phone":"+86 13352452086","email":"chszh@aliyun.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000013927","term":"Thrombosis"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M16376","name":"Thrombosis","asFound":"Thrombosis","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000018696","term":"Neuroprotective Agents"}],"ancestors":[{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M352286","name":"3-n-butylphthalide","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","asFound":"Over-the-counter (OTC)","relevance":"HIGH"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}